Hytrin
Formulated to alleviate symptoms of enlarged prostate to support urinary flow.
Strengths: 1 · 2 · 5mg
Where to Check Availability
Medicine details
- Conditions
- Therapeutic class
Alpha-1 Adrenoceptor Antagonist
- Pharmacological class
Alpha-blocker
- Contraindications
history of orthostatic hypotension; hypersensitivity to terazosin
- Minor side effects
dizziness; fatigue; asthenia; nasal congestion
- Moderate side effects
palpitations; peripheral oedema; headache; somnolence
- Dosage forms
Tablet
- Administration route
Oral use
- Patient summary
Formulated to alleviate symptoms of enlarged prostate to support urinary flow.
- Prescription status
POM
- Manufacturer
AbbVie
- Onset Time
1–2 hours
- Duration
24 hours
- Storage instructions
Store below 25°C.
- Drug interactions
antihypertensives; phosphodiesterase-5 inhibitors
- Age restrictions
Not applicable to children.
- Pregnancy and breastfeeding
Pregnancy: Not applicable (men's health). Breastfeeding: Not applicable.
Precautions and warnings
caution regarding initial dose hypotension; use with care when rising from sitting or lying position; may impair ability to drive
Serious side effects
syncope — requires immediate medical attention; priapism — requires immediate medical attention
Mechanism of action
Selectively blocks alpha-1-adrenoceptors in the prostate and bladder neck, reducing smooth muscle tone to improve urine flow.
Hytrin
Formulated to alleviate symptoms of enlarged prostate to support urinary flow.
Editorial Notes
- Active ingredient(s): Terazosin
- Listed indication(s): Benign Prostatic Hyperplasia, Hypertension
Usually available as
- 120 tablets - 1 mg206-1-mg-3140
- 60 tablets - 2 mg206-2-mg-3144
- 60 tablets - 5 mg206-5-mg-3149